Unfortunately, the administration of ABT263 in phase I/II clinical studies for adult cancers was associated with dose-limiting thrombocytopenia due to concomitant inhibition of anti-apoptotic BCL-XL, a key survival factor for circulating platelets [18–22]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.